Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival

2020 ◽  
Vol 122 (8) ◽  
pp. 1761-1769
Author(s):  
Thomas L. Sutton ◽  
Alexander Schlitt ◽  
Stuart K. Gardiner ◽  
Nathalie Johnson ◽  
Jennifer R. Garreau
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Residual Cancer ◽  
Cancer Burden ◽  
Residual Cancer Burden ◽  
Time To Surgery

scholarly journals Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

PLoS ONE ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. e0234191 ◽  
Author(s):  
Anne-Sophie Hamy ◽  
Lauren Darrigues ◽  
Enora Laas ◽  
Diane De Croze ◽  
Lucian Topciu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Prognostic Value ◽  
Breast Cancer Subtype ◽  
Residual Cancer ◽  
Cancer Burden ◽  
Residual Cancer Burden ◽  
Cancer Subtype

Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy

2019 ◽  
Vol 179 (1) ◽  
pp. 11-23 ◽  
Author(s):  
Clémence Pinard ◽  
Marc Debled ◽  
Houda Ben Rejeb ◽  
Valérie Velasco ◽  
Christine Tunon de Lara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Cancer ◽  
Cancer Burden ◽  
Residual Cancer Burden ◽  
Tumor Infiltrating Lymphocyte

Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 607-607 ◽  
Author(s):  
M. Chavez-Mac Gregor ◽  
R. Hubbard ◽  
F. Meric-Bernstam ◽  
S. S. Shinde ◽  
J. K. Litton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Residual Cancer ◽  
Cancer Burden ◽  
Residual Cancer Burden

Validation of the Residual Cancer Burden Index as a prognostic tool in women with locally advanced breast cancer treated with neoadjuvant chemotherapy

2021 ◽  
pp. jclinpath-2021-207771
Author(s):  
Juliana Pierobon Gomes da Cunha ◽  
Rodrigo Goncalves ◽  
Fernando Silva ◽  
Fernando Nalesso Aguiar ◽  
Bruna Salani Mota ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Molecular Subtype ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Clinical Staging ◽  
Residual Cancer ◽  
Cancer Burden ◽  
Residual Cancer Burden

AimsTo correlate the ‘Residual Cancer Burden’ (RCB) index with overall survival (OS) and disease-free survival (DFS) in women undergoing neoadjuvant chemotherapy at the Cancer Institute of the State of São Paulo.MethodsWe analysed the medical records of patients with breast cancer who underwent neoadjuvant chemotherapy and breast surgery, from 2011 to December 2017. Variables analysed were age, clinical and pathological staging, molecular subtype, number of recurrences or metastases, number of deaths, value and class of the RCB index. We used the Kaplan-Meier and the log-rank statistics to evaluate the possible association between RCB and OS and DFS. A regression model was used to determine the independent association of the RCB with the outcomes controlling for confounding factors.Results347 patients were included in the analysis with a mean age of 49.39 years. Initial clinical staging was T3 in 57.9% of patients and 43.8% of patients had N1 axillary status. Survival analysis showed a statistically significant better prognosis for the RCB 0 (pCR) subgroup compared with RCB 1, 2 and 3 (log rank p=0.01). In a multivariate analysis, only the RCB classification showed a statistically significant correlation with DFS (RCB 1, HR 6.9, CI 1.9 to 25.4, p=0.004; RCB 2, HR 4.2, CI 1.6 to 10.8, p=0.03; and RCB 3, HR 7.6, CI 2.76 to 20.8, p=0.00).ConclusionWe demonstrated a positive and significant relationship between the RCB index and the risk of relapse and death.

Sign in / Sign up

Export Citation Format

Share Document